“I'd rather see the resources put into looking to see if we can get people's weight down and preventing people getting to this weight in the first place,” Dr. Logue said.
The pravastatin trial and the first 5 years of follow-up were funded by the drug's manufacturer, Bristol-Myers Squibb and Sankyo. The final years of follow-up and Dr. Logue and her colleagues' analysis were funded by the Scottish government and a grant from Scotland's Chest, Heart, and Stroke Association, respectively. Dr. Logue and her colleagues said they had no financial disclosures.